← Catalyst calendarMTVA biotech catalysts & pipeline
METAVIA INC · Data as of 2026-09-08
Upcoming catalysts
vanoglipel (DA-1241) — FDA meeting
H2 2026
The Company is currently working to schedule an End-of-Phase 2 meeting with the FDA during the second half of 2026 to discuss the clinical development pathway for the vanoglipel combination therapy.
Source filingDA-1726 — Topline data
Q4 2026
16-Week Topline Data Expected in the Fourth Quarter of 2026
Source filingvanoglipel (DA-1241) — Full data
Q4 2026
We are expecting to finalize the Clinical Study Report of the Phase 2a clinical trial in the fourth quarter of 2026.
Source filingExplore the free biotech catalyst calendar